



Supplementary Material

NS5A Resistance Associated Mutations to Daclatasvir in Hepatitis C Virus Genotype 3a Treatment Naive and SOF/DCV Treatment Failure Patients

Saima Younas and Aleena Sumrin*

Centre for Applied Molecular Biology, University of the Punjab, 87 West Canal Bank Road Thokar Niaz Baig, Lahore, Pakistan.

Supplementary Table SI. Amino acid mutations identified in the study group.

Substitution/ Mutation	Treatment naive group No (%)	SOF/DCV treated group No (%)
A17S	16(51.6%)	3(23.0%)
A21T	22(70.9%)	11(84.6%)
S24A	-	1(7.6%)
M28T	-	-
A30T	-	1(7.6%)
L31V/F/I	-	-
P58T	-	1(7.6%)
A62R/S/T/V	26(83.8%)	11(84.6%)
T64A	10(32.2%)	8(61.5%)
H85Y	12(38.7%)	3(23%)
Y93H	-	2(15.3%)
S98G	-	3(23%)
S103P	12(38.7%)	9(69.2%)
E137G	6(19.3%)	6(46.1%)
A147P	6(19.3%)	3(23.0%)
D172E	14(45.1%)	9(69.2%)
M176T/V/S	7(22.5%)	6(46.1%)
L179M	5(16.1%)	7(53.8%)
H180N	17(54.8%)	6(46.1%)
T183A/V	22(70.9%)	8(61.5%)
L158F/I	4(12.9%)	4(30.7%)
R204T	4(12.9%)	2(15.3%)
T213A	5(16.1%)	1(7.6%)
K20R	2(6.4%)	1(7.6%)
K41R	7(22.5%)	-
A25T/C/S	2(6.5%)	-

* Corresponding author: aleena.camb@pu.edu.pk
0030-9923/2024/0006-2601 \$ 9.00/0



Copyright 2024 by the authors. Licensee Zoological Society of Pakistan.

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).